All Updates

All Updates

icon
Filter
Funding
Product updates
iOnctura includes oral TGF-β pathway inhibitor to its pipeline
Precision Medicine
May 3, 2023
This week:
Product updates
Burcon unveils canola protein isolate for egg replacement
Plant-based Dairy & Egg
Yesterday
Product updates
Bene Meat Technologies produces first cultivated burger at parity with premium beef
Cell-cultured Meat
Yesterday
Geographic expansion
Regulation/policy
The Better Meat Co. expands to Asia with Singapore approval for Rhiza mycoprotein
Plant-based Meat
Yesterday
Listing
Pony.ai files for US IPO
Auto Tech
Yesterday
Product updates
MineOS launches DSR management 2.0
Digital Privacy Tools
Yesterday
Product updates
LatticeFlow launches the first evaluation framework for EU AI Act compliance
Generative AI Infrastructure
Yesterday
Product updates
Cognitive3D launches custom dashboards for XR analytics
Extended Reality
Oct 16, 2024
Funding
Mindtech raises GBP 4.4 million in funding to develop AI vision technology
Extended Reality
Oct 16, 2024
Partnerships
Zscaler and Okta partner to enhance zero trust security initiatives
Identity & Access Management
Oct 16, 2024
Partnerships
Zscaler and Okta partner to enhance zero trust security initiatives
Next-gen Cybersecurity
Oct 16, 2024
Precision Medicine

Precision Medicine

May 3, 2023

iOnctura includes oral TGF-β pathway inhibitor to its pipeline

Funding
Product updates

  • Drug discovery company iOnctura exercised an exclusive option with Clavius Pharmaceuticals, adding the novel oral TGF-β pathway inhibitor, IOA-359, to its pipeline. The company also received a grant from Health Holland and KWF in collaboration with the University of Twente. iOnctura is solely responsible for global development and commercialization of the small molecule inhibitor.

  • The funding will be used for the development of IOA-359 and the characterization of resistance mechanisms.

  • iOnctura is a clinical-stage biotech company focused on developing selective cancer therapies that target critical tumor survival pathways. They are using data-driven precision oncology methods to design combination treatments that overcome resistance pathways. iOnctura has two candidates in mid-stage clinical development, IOA-244 and IOA-289, while IOA-359 is undergoing preclinical preparations. The company is headquartered in Amsterdam, with a subsidiary in Geneva.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.